Testosterone Enanthate Safety in Older Adults (50, 64)

Why the 50, 64 Age Window Demands Extra Scrutiny

Men between 50 and 64 sit at a clinical inflection point. Testosterone levels decline roughly 1 to 2% per year after age 30, and by age 55 approximately 20% of men meet laboratory criteria for hypogonadism based on total testosterone below 300 ng/dL [1]. At the same time, this decade brings rising prevalence of hypertension, dyslipidemia, type 2 diabetes, and subclinical atherosclerosis.

The overlap of genuine androgen deficiency with accumulating cardiovascular risk factors creates a prescribing challenge that does not exist in younger men. The Endocrine Society's 2018 clinical practice guideline explicitly recommends against testosterone therapy in men planning to conceive and in those with recent cardiovascular events, while calling for individualized risk-benefit assessment in men with significant comorbidities [2]. For the 50-to-64 cohort specifically, the guideline emphasizes confirming the diagnosis with two separate morning testosterone measurements before initiating therapy.

Polypharmacy adds another layer. A 2019 CDC analysis found that adults aged 45 to 64 fill an average of 4.7 prescriptions per month, raising the probability of interactions with anticoagulants, antihypertensives, and hypoglycemic agents [3]. Short sentence for emphasis: polypharmacy changes everything.

Cardiovascular Safety: What TRAVERSE Actually Showed

The single most important dataset for this question is the TRAVERSE trial. Published in the New England Journal of Medicine in 2023, TRAVERSE randomized 5,246 men aged 45 to 80 (mean age 63.3) with hypogonadism and either preexisting cardiovascular disease or high cardiovascular risk to receive 1.62% testosterone gel or placebo [4]. Over a median follow-up of 33 months, the primary composite endpoint of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 7.0% of the testosterone group vs. 7.3% of the placebo group (hazard ratio 0.96; 95% CI, 0.78, 1.17).

This result was noninferiority, not superiority. Testosterone did not reduce cardiovascular events, but it did not increase them either. The trial's prespecified noninferiority margin was met.

A secondary finding warrants attention. The testosterone group had a higher incidence of pulmonary embolism (0.9% vs. 0.5%), atrial fibrillation (3.5% vs. 2.4%), and acute kidney injury (2.3% vs. 1.5%) [4]. None of these secondary endpoints were powered for definitive conclusions, but they reinforce the need for clinical vigilance in men with thrombotic risk or renal impairment.

Dr. Shalender Bhasin, principal investigator of TRAVERSE and professor of medicine at Harvard Medical School, stated: "The findings provide reassurance that testosterone replacement therapy in men with hypogonadism does not increase short-to-intermediate-term risk of major adverse cardiovascular events, but clinicians should remain attentive to venous thromboembolic signals" [4].

Hematocrit and Polycythemia: The Most Common Laboratory Risk

Erythrocytosis is the most frequently encountered safety concern with testosterone therapy across all age groups, and the 50-to-64 population is no exception. Testosterone stimulates erythropoietin production in the kidneys, which in turn increases red blood cell mass. When hematocrit exceeds 54%, the risk of thromboembolic events rises.

In the T-Trials (N=790, men ≥65), polycythemia was observed at meaningfully higher rates in testosterone-treated participants than in placebo groups [1]. The Endocrine Society guideline sets a hematocrit threshold of 54% as the point at which testosterone should be dose-reduced or temporarily withheld [2]. Separate analysis of insurance claims data published in JAMA Internal Medicine found that the risk of venous thromboembolism was highest in the first six months of therapy, particularly in men with pre-existing clotting disorders [5].

Practical monitoring protocol:

• Baseline hematocrit and CBC before first injection
• Repeat at 3 months after initiation
• Every 6 to 12 months thereafter
• If hematocrit reaches 52%, consider dose reduction
• If hematocrit exceeds 54%, hold therapy and evaluate for phlebotomy or switch to a lower-dose transdermal formulation

Men aged 50 to 64 who smoke, have obstructive sleep apnea, or live at high altitude face compounding erythrocytosis risk. These patients may benefit from starting at the lower end of the dosing range (100 mg weekly rather than 200 mg) and monitoring hematocrit monthly for the first three months.

Prostate Safety and PSA Monitoring

The relationship between testosterone therapy and prostate cancer risk has been debated for decades. Current evidence does not support the historical assumption that testosterone replacement increases prostate cancer incidence, but the data require careful interpretation.

A 2016 meta-analysis in Medicine encompassing 22 randomized controlled trials (N=2,351) found no statistically significant difference in prostate cancer rates between testosterone-treated men and controls (OR 0.87; 95% CI, 0.30, 2.53) [6]. The TRAVERSE trial reported similar prostate cancer incidence in both groups: 1.0% testosterone vs. 0.9% placebo over 33 months [4].

The AUA/Endocrine Society 2018 guidelines recommend the following PSA monitoring framework for men on testosterone therapy [2]:

1. Obtain baseline PSA before initiating treatment
2. Repeat PSA at 3 to 6 months
3. Refer to urology if PSA rises >1.4 ng/mL above baseline within 12 months
4. Refer to urology if PSA velocity exceeds 0.75 ng/mL per year
5. Annual digital rectal exam in men over 50

One clinical subtlety: testosterone does not create prostate cancer, but it can accelerate the growth of pre-existing occult lesions. This is why a baseline PSA and, in some cases, a multiparametric MRI before initiating TRT in men over 50 is becoming standard practice at many academic urology centers.

Drug Interactions and Polypharmacy Considerations

For the 50-to-64 age bracket, drug interactions with testosterone enanthate represent a practical safety domain that receives too little attention.

Anticoagulants (warfarin, apixaban, rivarelbaan). Testosterone may potentiate the effects of warfarin by altering hepatic metabolism of vitamin K-dependent clotting factors. The FDA prescribing information for testosterone enanthate carries a specific warning about increased INR in patients on oral anticoagulants [7]. Men on warfarin starting testosterone need INR checks at 1, 2, and 4 weeks after initiation, then monthly until stable.

Insulin and oral hypoglycemics. Testosterone improves insulin sensitivity. The TIMES2 trial (N=220) demonstrated a reduction in HOMA-IR of 15.2% with testosterone gel over 12 months in men with type 2 diabetes or metabolic syndrome [8]. While beneficial, this means insulin doses or sulfonylurea dosing may require downward adjustment to prevent hypoglycemia.

Corticosteroids. Concurrent use of corticosteroids with testosterone can increase fluid retention. In men with congestive heart failure (NYHA class III or IV), the combination is relatively contraindicated.

5-alpha reductase inhibitors (finasteride, dutasteride). These drugs reduce conversion of testosterone to dihydrotestosterone by 60 to 70%. Concurrent TRT may partially counteract the prostate-size reduction effect of finasteride, and combined PSA interpretation becomes unreliable. Coordinate with urology.

Hepatic, Renal, and Metabolic Monitoring

Testosterone enanthate is metabolized primarily by the liver, although intramuscular administration bypasses first-pass hepatic metabolism (unlike oral methyltestosterone, which carries significant hepatotoxicity risk). The injectable ester formulation makes clinically significant liver injury rare, but baseline and annual hepatic function panels remain part of standard practice.

Regarding lipids, testosterone therapy tends to reduce HDL cholesterol by 5 to 15% while having variable effects on LDL and triglycerides [2]. A systematic review in Clinical Endocrinology found that intramuscular testosterone consistently decreased HDL-C more than transdermal formulations [9]. For men aged 50 to 64 already on statin therapy, the clinical significance of a modest HDL reduction is debatable, but it should be documented and tracked.

Dr. Bradley Anawalt, chief of medicine at the University of Washington Medical Center and co-author of the Endocrine Society guideline, has noted: "In men over 50 with dyslipidemia, the HDL reduction from testosterone therapy is generally small and unlikely to change cardiovascular risk classification, but it should still be factored into the global risk assessment" [2].

Renal function deserves attention because testosterone-induced erythrocytosis increases blood viscosity, which may impair glomerular filtration in men with pre-existing chronic kidney disease (CKD stages 3, 5). The TRAVERSE trial flagged a higher rate of acute kidney injury in the testosterone arm (2.3% vs. 1.5%), although the absolute numbers were small [4]. Serum creatinine and eGFR at baseline and every 6 months is a reasonable approach for men with any CKD history.

Bone Density Benefits in This Age Group

While the primary discussion concerns safety, bone outcomes provide an important benefit context. The T-Trials bone substudy used quantitative CT to measure volumetric bone mineral density in 211 men aged 65 and older with testosterone levels below 275 ng/dL [10]. After 12 months of testosterone gel, spine trabecular vBMD increased by 7.5% compared to 0.8% in the placebo group, and hip trabecular vBMD increased by 3.2%.

These findings carry implications for the 50-to-64 cohort because bone loss accelerates during this decade. Men in this age range who have confirmed hypogonadism alongside T-scores between -1.0 and -2.5 (osteopenia) may derive dual benefit from testosterone enanthate therapy. The bone data do not justify prescribing testosterone solely for bone density, but they do strengthen the risk-benefit calculation in hypogonadal men who also have low bone mass.

Contraindications Specific to This Age Group

Absolute contraindications for testosterone therapy in men aged 50 to 64 include [2]:

• Prostate or breast cancer (active or history). Despite evolving data suggesting select survivors may be candidates, current guidelines maintain this as a contraindication.
• Hematocrit >54% at baseline. Treat the polycythemia first.
• Untreated severe obstructive sleep apnea. Testosterone can worsen apnea severity and must not be started until the patient is adherent to CPAP or oral appliance therapy.
• Uncontrolled heart failure (NYHA class III, IV). The TOM trial in frail elderly men was halted early due to excess cardiovascular events, though participants were older (mean age 74) and more debilitated than the typical 50-to-64-year-old candidate [11].
• Desire for fertility. Exogenous testosterone suppresses spermatogenesis. Men in this age group who wish to preserve fertility should be offered clomiphene citrate or hCG as alternatives.

Relative contraindications requiring specialist consultation: severe lower urinary tract symptoms (IPSS >19), thrombophilia, poorly controlled hypertension (systolic >160 mmHg consistently), and active venous thromboembolism within the preceding 6 months.

A Practical Monitoring Schedule

The following schedule synthesizes AUA and Endocrine Society recommendations for men aged 50 to 64 on testosterone enanthate [2][7]:

| Timepoint | Tests | |---|---| | Baseline | Total T (two morning draws), free T, LH/FSH, CBC, CMP, lipid panel, PSA, DRE, DEXA if indicated, sleep study if OSA suspected | | 6 weeks | Trough total T (drawn morning of injection day), symptom assessment | | 3 months | CBC (hematocrit focus), PSA, liver panel, fasting glucose | | 6 months | Total T (trough), CBC, PSA, lipid panel, blood pressure | | 12 months | Full panel: T, CBC, CMP, lipids, PSA, DRE, assess symptom response | | Annually | Repeat 12-month panel; DEXA every 2 years if baseline osteopenia |

Dose adjustments at 6 weeks should target a trough testosterone of 400 to 600 ng/dL. Supraphysiologic peaks (>1 to 000 ng/dL) increase polycythemia risk without improving symptom outcomes.